PT - JOURNAL ARTICLE AU - Valeria Genoud AU - Martin Stortz AU - Ariel Waisman AU - Bruno G. Berardino AU - Paula Verneri AU - Virginia Dansey AU - Melina Salvatori AU - Federico Remes Lenicov AU - Valeria Levi TI - Extraction-free protocol combining Proteinase K and heat inactivation for detection of SARS-CoV-2 by RT-qPCR AID - 10.1101/2020.12.16.20248350 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.16.20248350 4099 - http://medrxiv.org/content/early/2020/12/16/2020.12.16.20248350.short 4100 - http://medrxiv.org/content/early/2020/12/16/2020.12.16.20248350.full AB - Real-time reverse transcription PCR (RT-qPCR) is the gold-standard technique for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection in nasopharyngeal swabs specimens. The analysis by RT-qPCR usually requires a previous extraction step to obtain the purified viral RNA. Unfortunately, RNA extraction constitutes a bottleneck for early detection in many countries since it is expensive, time-consuming and depends on the availability of commercial kits. Here, we describe an extraction-free protocol for SARS-CoV-2 detection by RT-qPCR from nasopharyngeal swab clinical samples in saline solution. The method includes a treatment with proteinase K followed by heat inactivation (PK+HID method). We demonstrate that PK+HID improves the RT- qPCR performance in comparison to the heat-inactivation procedure. Moreover, we show that this extraction-free protocol can be combined with a variety of multiplexing RT-qPCR kits. The method combined with a multiplexing detection kit targeting N and ORF1ab viral genes showed a sensitivity of 0.99 and a specificity of 0.99 from the analysis of 106 positive and 106 negative clinical samples. In conclusion, PK+HID is a robust, fast and inexpensive procedure for extraction-free RT-qPCR determinations of SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding Statement1) Agencia Nacional de Promocion de la Investigacion, el Desarrollo Tecnologico y la Innovacion (ANPCyT). Grant: PICT 2016-0828 to V.L. 2) Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET). Grant: PIP 2014-11220130100121CO to V. L. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study used the remaining volume of anonymized samples that had been collected for clinical diagnosis. Under these circumstances, and for studies involving development of COVID-19 diagnostic tools, our IRB (the Research Ethics Committee from Fundacion Huesped in Buenos Aires, Argentina) deemed unnecessary to obtain informed consent from the patients.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is included within the manuscript and supplementary information.